Description

• General description: Desmethylolanzapine is the primary metabolite of olanzapine, marketed as the atypical antipsychotic Zyprexa®for the treatment of schizophrenia and bipolar disorder. This new certified solution standard is suitable for use in LC or GC applications including clinical toxicology analysis, forensic testing, or therapeutic drug monitoring.
• Application: Desmethylolanzapine Dihydrochloride Solution: This specialized solution is pivotal in neuropharmacology research, primarily used to study the pharmacokinetics and metabolic pathways of olanzapine, a prominent antipsychotic medication used in the treatment of schizophrenia and bipolar disorder.Olanzapine Metabolite Research: As an active metabolite of olanzapine, desmethylolanzapine dihydrochloride provides critical insights in antipsychotic drug studies, helping to understand the drug′s efficacy, side effects, and metabolism.Antipsychotic Drug Studies: This solution is used extensively in biochemical assays to evaluate the interaction of olanzapine metabolites with various neurotransmitter systems, aiding in the development of more effective and safer antipsychotic treatments.Biochemical Assay Reagents: Desmethylolanzapine dihydrochloride serves as a reagent in various biochemical assays, facilitating research into the molecular mechanisms of psychiatric disorders and the therapeutic potential of benzodiazepines.Neuropharmacology Research Chemicals: This compound is a key research chemical in neuropharmacological studies, used to simulate and study the effects of long-term antipsychotic medication usage on the brain and body.
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany